Open Access

Is alcohol beneficial or harmful for cardioprotection?

  • Raj Lakshman1, 2Email author,
  • Mamatha Garige2,
  • Maokai Gong2,
  • Leslie Leckey1,
  • Ravi Varatharajalu2 and
  • Samir Zakhari3
Genes & NutritionStudying the relationship between genetics and nutrition in the improvement of human health20095:161

https://doi.org/10.1007/s12263-009-0161-2

Received: 24 July 2009

Accepted: 18 November 2009

Published: 13 December 2009

Abstract

While the effects of chronic ethanol consumption on liver have been well studied and documented, its effect on the cardiovascular system is bimodal. Thus, moderate drinking in many population studies is related to lower prevalence of coronary artery disease (CAD). In contrast, heavy drinking correlates with higher prevalence of CAD. In several other studies of cardiovascular mortalities, abstainers and heavy drinkers are at higher risk than light or moderate drinkers. The composite of this disparate relation in several population studies of cardiovascular mortality has been a “U-” or “J-”shaped curve. Apart from its ability to eliminate cholesterol from the intima of the arteries by reverse cholesterol transport, another major mechanism by which HDL may have this cardioprotective property is by virtue of the ability of its component enzyme paraoxonase1 (PON1) to inhibit LDL oxidation and/or inactivate OxLDL. Therefore, PON1 plays a central role in the disposal of OxLDL and thus is antiatherogenic. Furthermore, PON1 is a multifunctional antioxidant enzyme that can also detoxify the homocysteine metabolite, homocysteine thiolactone (HTL), which can pathologically cause protein damage by homocysteinylation of the lysine residues, thereby leading to atherosclerosis. We demonstrated that moderate alcohol up regulates liver PON1 gene expression and serum activity, whereas heavy alcohol consumption had the opposite effects in both animal models and in humans. The increase in PON1 activity in light drinkers was not due to preferential distribution of high PON1 genotype in this group. It is well known that wine consumption in several countries shows a remarkable inverse correlation to local rates of CAD mortality. Significantly, apart from its alcohol content, red wine also has polyphenols such as quercetin and resveratrol that are also known to have cardioprotective effects. We have shown that quercetin also up regulates PON1 gene in rats and in human liver cells. The action of quercetin seems to be mediated via the active form of the nuclear lipogenic transcription factor, sterol-regulatory element-binding protein 2 (SREBP2) that is translocated from endoplasmic reticulum to the nucleus. However, the mechanism of action of ethanol-mediated up-regulation of PON1 gene remains to be elucidated. We conclude that both moderate ethanol and quercetin, the two major components of red wine, exhibit cardioprotective properties via the up-regulation of the antiatherogenic gene PON1.

Keywords

Coronary artery diseaseParaoxonaseHomocysteine thiolactonaseSterol-regulatory element-binding proteinEthanolQuercetin

Introduction

While the deleterious effects of chronic heavy ethanol consumption on liver have been well studied and documented, its beneficial versus harmful effects on the cardiovascular system is bimodal. We have previously reviewed the health risks and potential benefits of moderate alcohol consumption, with particular focus on the areas of cardiovascular disease, breast cancer, obesity, birth defects, breastfeeding and aging [1], while a more recent review [2] has summarized the benefits of moderate alcohol consumption even in diabetic subjects. Thus, light to moderate drinking is cardioprotective, whereas heavy drinking is correlated with cardiovascular abnormalities. The main goal of this review is to present the current status of the prevalence of coronary artery disease (CAD) in moderate versus heavy drinkers with special emphasis on the antiatherogenic enzyme, paraoxonase, and its gene regulation by ethanol and flavonoids, mainly quercetin and resveratrol, the main components of red wine.

Alcohol and HDL versus LDL

It is now well known that CAD is the principal cause of mortality and morbidity in developed countries, and several features of this metabolic disorder are due to the accumulation of low-density lipoprotein (LDL), the atherogenic lipoprotein. The role of oxidative stress as a major contributor to the atherogenic process has been elegantly reviewed [3, 4]. Thus, oxidation of LDL to form oxidized LDL (OxLDL) results in its massive uptake by peripheral macrophages (i.e. scavenger pathway), leading to the formation of foam cells. The accumulation of these foam cells in the intima of the arterial wall results in a gradual decrease in arterial lumen and eventually occlusion of the artery causing myocardial infarction (MI). On the other hand, high-density lipoprotein (HDL) is antiatherogenic because of its ability to remove cholesterol from peripheral tissues to the liver for degradation, a process called “Reverse Cholesterol Transport” (RCT).

Numerous cross-sectional and intervention studies including ours have documented an increase in the plasma HDL-C concentration as a result of chronic moderate ethanol consumption [58]. Correcting for smoking as another risk factor, it has been found that a strong negative correlation still exists between moderate alcohol consumption and the incidence of CAD [911]. There are conflicting reports with regard to whether HDL2 or HDL3 subfraction is increased after moderate alcohol intake [1214]. According to the current concept, relatively lipid-poor HDL3 acquires free-cholesterol and other phospholipids from the peripheral tissues. In the blood compartment, the free-cholesterol component of HDL3 is esterified by lecithin cholesterol acyltransferase (LCAT) to yield lipid-rich HDL2, which is efficiently taken up by the liver via the HDL receptor, scavenger receptor class B1 (SRB1). Significantly, both HDL2 and HDL3 fractions are markedly decreased in severe alcohol-induced liver diseases [15]. Furthermore, heavy alcohol drinkers do not seem to be protected against CAD [16]. Our ongoing studies have established that chronic ethanol markedly decreased the ApoE content of plasma HDL [17], and this has been confirmed by others [18]. Furthermore, we have shown that the RCT function of HDL is impaired in both chronic alcohol-fed rats [19] and human alcoholics [20].

It has been shown that LDL oxidation is increased in regular alcohol abusers [21]. Acetaldehyde, the first metabolite of ethanol, also modifies lysine residues of LDL [22], and the product is rapidly catabolized in the plasma [23]. Since modified LDL is taken up by macrophages via the scavenger pathway, it is reasonable that the ethanol-mediated increase in modified LDL (either by peroxidative products HNE and MDA or by acetaldehyde, the first product of ethanol oxidation) could be more atherogenic than native LDL. Our studies [24] showed that cholesterol uptake by the macrophage system from acetaldehyde-modified LDL was similar to that from HNE-modified LDL.

Ethanol and lipid peroxidation

Ethanol, in addition to its normal oxidation by the alcohol dehydrogenase (ADH) pathway, is also oxidized by the liver microsomal ethanol-oxidizing system (MEOS) pathway [25] by an ethanol-inducible cytochrome P-450 (Cyp2E1). This contributes to ethanol tolerance and forms toxic-free radicals. The role of free radicals in the manifestation of alcohol-mediated liver damage has been recognized ever since DiLuzio et al. [2628] showed that antioxidants protected rats from the deleterious effects of fatty liver induced by even an acute dose of ethanol. Cederbaum [29] has pointed out that the formation of hydroxyethyl free radicals during the oxidation of ethanol may cause more damage in biological systems than the hydroxyl radical alone. All these studies point out the importance of lipid peroxidation in the alcohol-mediated human diseases. All of these aspects have been reviewed [30, 31]. Highly reactive aldehydes such as 4-hydroxynonenal (HNE) and malondialdehyde (MDA), generated during the peroxidative process, conjugate with the lysine residues of Apo B (the protein component of LDL) leading to the formation of oxidized LDL (OxLDL), which has a strong emission maximum at 430 nm when excitation is performed at 360 nm [32]. Thus, the formation of OxLDL can be quantitatively monitored fluorimetrically. LDL oxidation in vitro can also be more easily performed by monitoring the formation of conjugated dienes spectrophotometrically at 230 nm [33].

Alcohol and CAD

Whereas heavy drinking is associated with higher prevalence of cardiomyopathy, [3436], hypertension [37], hemorrhagic stroke [38] and cardiac dysrythmias [39], lighter drinking in many population studies cited in recent reports [40, 41] is related to lower prevalence of CAD. In several other studies of cardiovascular mortalities [42, 43], abstainers and heavy drinkers are at higher risk than light or moderate drinkers, possibly because of favorable effects of moderate alcohol on circulating high-density lipoproteins (HDL) level. The composite of this disparate relation in several population studies of cardiovascular mortality has been a “U-” or a “J-”shaped curve. The possibility that lighter alcohol use protects against CAD is supported by plausible hypothetical mechanisms. These include a favorable effect on HDL cholesterol concentration [44, 45] and apolipoproteins [45, 46]. A number of studies have shown the antiatherogenic effects and decreased incidence of peripheral arterial disease [47], a result of moderate drinking based on coronary angiography [48], coronary calcium evaluated by computerized tomography [49], ultrasound imaging of carotid artery [50]. A widely publicized [51] hypothesis was that many abstainers are former heavy drinkers who abstain because of symptoms (sick quitters), CAD diagnosis or other traits that predispose to CAD. Thus, several studies have clearly demonstrated significant reduction in CAD risk and in the incidence of myocardial infarction (MI) as a result of moderate alcohol intake regardless of the gender [5255]. Significantly, light to moderate drinking seems to reduce the incidence of MI not only in diabetics with known CAD and in a subpopulation that had healthy lifestyle habits such as eating health foods, exercising approximately 30 min/day, no smoking and body mass index <25 kg/m2, but also in hypertensive subjects [55, 56]. The benefits of moderate drinking to reduce heart failure have been summarized [57]. However, it must be pointed out that even two drinks/day can substantially increase the blood pressure in hypertensive subjects [58].

Frequency of ethanol intake in cardioprotection

Moderate alcohol intake has been shown to improve cardiovascular health regardless of the gender, in contrast to intermittent drinking [53, 5962]. Thus, daily intake of moderate alcohol has been shown to reduce CAD risk by 37% compared to alcohol consumption just once a week [53]. This has been attributed to alcohol-mediated improvement in insulin sensitivity and HDL cholesterol [60]. It is possible that a better postprandial glucose metabolism associated with light to moderate drinking may be responsible for the benefits associated with moderate drinking prior to or along with meals [61]. In contrast, it should be recognized that occasional drinking as well as binge drinking increase risk of MI and other all-cause mortality [6163]. It is significant to point out that there was a 2-fold increase in MI in subjects who consumed at least five drinks per day compared to non-drinkers [64]. Cardioprotective dosage of alcohol intake is considered to be 1 or two drinks per day for men and one drink per day for women [53, 65, 66]. A drink is equivalent to approximately 14 g of ethanol, which would be equivalent to 12 oz beer or 5 oz wine or 1.5 oz 80-proof spirits. Again, it must be emphasized that the cardioprotective effects of ethanol is manifested generally when it is consumed in moderate amounts on a daily basis [67]. Nonetheless, because of its addictive nature, caution must be exercised in recommending daily moderate intake of alcohol unless there is no family history of alcohol abuse in spite of the known CVD protection by moderate drinking [53]. Unfortunately, it is impossible to predict the susceptibility of any individual to become alcohol-dependent [47]. Binge drinking as well as alcohol abuse have been reported to have risen in recent years [1]. More importantly, heavy drinking is responsible not only for traffic accidents, but also for the increased incidence of cardiovascular complications, alcoholic liver diseases leading to fibrosis and cirrhosis, breast and GI tract cancers and all-cause mortality [1, 6163]. It is a well known fact that alcohol abuse is the root cause for innumerable number of individuals ruining their lives and associated burden to the immediate families and the society at large. As a result, prospective randomized clinical trials have been difficult to carry out to truly evaluate the cardioprotective effects of moderate alcohol.

Does alcohol per se or do flavonoid components of alcoholic beverages also protect against heart disease?

A number of studies have reported that alcohol per se has significant protective effect against vascular disease in its own right [53, 59, 6871]. These effects can probably be attributed to the potential for alcohol to increase protective HDL cholesterol levels and decrease platelet aggregation. However, the possibility of other components, particularly the bioflavonoids in red wine [72] could also confer its cardioprotective property. The Zutphen Elderly Study [73] assessed the flavonoids intake of 805 men aged 65–84 in 1985 and followed them up for 5 years. The flavonoids intake analyzed in tertiles was significantly inversely associated with death from coronary heart disease (P = 0.015) and showed a trend toward an inverse association with myocardial infarction (P = 0.08). The relative risk of coronary heart disease in the highest versus the lowest tertile of flavonoids intake was 0.42 (95% Cl 0.20–0.88). This relationship persisted after controlling for all other relevant coronary risk factors. Knekt et al. [74] studied 5,133 Finnish men and women aged 30–69 recruited between 1967 and 1972. The flavonoids intake was calculated from the reported dietary recall of subjects for the year prior to entry into the study and then related to coronary and total mortality over the subsequent 26 years. For women, there was a significant inverse gradient of risk for coronary and total mortality with flavonoids intake. The relative risk between the highest and lowest quarters of intake after adjusting for other coronary risk factors was 0.69 (95% Cl 0.53–0.90) for total mortality and 0.54 (95% Cl 0.33–0.87) for coronary mortality. For men, the corresponding values were 0.76 (95% Cl 0.63–0.93) and 0.78 (95% Cl 0.56–1.08). It was suggested that since the intake of vitamin C in the Finnish diet was low, dietary flavonoids might offer an alternative source of antioxidants.

Red wine protects against heart disease: the French paradox

Flavonoids are derived from many sources in the human diet including fruit, vegetables, red wine and tea. Red wine is a particularly rich source of flavonoids. Previous calculations have suggested that the addition of two glasses of red wine to the Western diet will increase its flavonoids content by 40% [74]. Studying the potential impact of red wine flavonoids on coronary heart disease is complicated by the presence of other wine constituents such as alcohol and sugars. More importantly, light drinking favors the destruction of OxLDL by up-regulation of antiatherogenic enzyme, paraoxonase (PON1), as shown by us [24].

However, there have been many claims that there may be benefits associated with the flavonoids content of red wine over and above the effect of alcohol. One of the earliest experiments to suggest this examined the effect of feeding rabbits a high cholesterol diet for 3 months while also administering alcohol, beer, white wine, red wine or water. These beverages reduced the atherosclerotic lesions over the subsequent 3 months to 75, 83, 67 and 40%, respectively, of those found in the water-drinking controls [75].

The epidemiological evidence for a specific protective effect of flavonoid-rich alcoholic beverages is rather more confused [76]. In most countries, intakes of saturated fat are directly associated with mortality from coronary heart disease. However, some countries appear to defy this general association. The most notable exception is France where in spite of high fat intakes, there has been a low incidence of coronary heart disease [77]. This circumstance has come to be known as the ‘French Paradox’ and has stimulated interest in local lifestyle factors that may protect the French against heart disease. A likely candidate was the preference of the French for regular consumption of red wine that offers not only the benefits of moderate alcohol consumption but also the potential benefits of a high flavonoids intake. Indeed, it has been reported that wine consumption in several countries shows a remarkable inverse correlation to local rates of coronary heart disease mortality [78]. It must, however, be cautioned that smoking combined with drinking may predispose such individuals to esophageal cancer, while excessive drinking is likely to lead to liver diseases. More recently, there have been reports showing the preservation of serum PON activity and protection against LDL oxidation by wine flavonoids in mice [79, 80]. A recent clinical trial demonstrated the beneficial effects of grape extract on the susceptibility of LDL oxidation in heavy smokers [81].

Central role of paraoxonase

In mammals, the paraoxonase gene family includes at least 3 members: PON1, PON2 and PON3 [82]. PON1 is the most predominant one among these that is tightly associated with HDL and has been shown to play a major role in the protective role of HDL against CAD [83]. Specifically, PON1 is believed to (i) prevent the oxidation of LDL to OxLDL and (ii) destroy the OxLDL to biologically inactive products. It is a calcium-dependent HDL-associated ester hydrolase that catalyzes the hydrolysis of organophosphates, aromatic carboxylic acid esters and carbamates [83].

It is now well known that PON1 is tightly associated with apolipoprotein A-I in HDL and has the highest activity in the liver and blood [83]. It has also been shown that PON is also associated with Apo J and, in fact, copurifies during the purification of Apo J. Serum PON1 activity varies widely between different animal species and among humans [84, 85]. It has also been shown that individuals with familial hypercholesterolemia and insulin-dependent diabetes mellitus have significantly lower levels of PON1 than do normal control individuals [86]. A low level of HDL-associated PON1 is also correlated with susceptibility to myocardial infarction, fish eye disease and tangier disease [87, 88]. A recent study [89] showed that aspirin markedly elevated PON1 activity both in mice and in rat hepatocytes. Most importantly, HDL-associated PON1 has also been reported to inhibit copper-induced lipid peroxidation in LDL [90]. PON2 and PON3 are two other variants that have also been shown to be very effective in protecting against LDL oxidation [91, 92]. However, PON2 has not been detectable in either HDL or VLDL fraction of plasma [91]. Although PON3 has been found in HepG2 cells [92] and rabbit serum, it has been estimated to be much less abundant in rodent and human serum when compared to that of PON1 [92]. Further, unlike PON1, PON3 is not regulated by oxidized lipids [93]. In view of all these, the physiological significance of PON2 and to some extent PON3 in the blood, when compared to that of PON1, in cardioprotection remains to be seen.

Paraoxonase is a multifunctional antiatherogenic enzyme

Paraoxonase is a multifunctional antioxidant enzyme tightly associated with HDL that exhibits not only the capacity to prevent LDL oxidation and destroy oxidized LDL [9497] but also can detoxify the homocysteine metabolite, homocysteine thiolactone (HTL), which can pathologically cause protein damage by homocysteinylation of the lysine residues, thereby leading to atherosclerosis [98, 99]. The importance of PON1 with respect to cardiovascular disease (CVD) is supported by our demonstration that moderate but not heavy alcohol intake in both animals and humans up regulates PON1 gene and activity accompanied by increased protection capacity of plasma HDL against LDL oxidation [24]. These results are consistent with the reports of increased serum PON1 activity in moderate drinkers [100]. Subsequently, we [101] and others [102] have shown a strong correlation between decreased homocysteine thiolactonase (HCTL) activity and the severity of CVD in type II diabetics.

Regulation of PON1 by sterol-regulatory element-binding proteins

Sterol-regulatory element-binding proteins (SREBPs) have been recognized as a new class of membrane-bound proteins that modulate lipid homeostasis [103]. Currently, three types of SREBPs exist, namely SREBP1a, SREBP1c and SREBP2. While SREBP1a and SREBP1c seem to control fatty acid pathway, SREBP2 regulates cholesterol biosynthetic pathway. SREBP1a and SREBP2 are present in most cultured cell lines, while SREBP1c and SREBP2 are present in liver and most intact tissues. Newly synthesized SREBP is inserted into the ER as an inactive protein. When the cellular cholesterol is low, SREBP is escorted into the Golgi by SREBP cleavage-activating protein (SCAP) where it is proteolytically cleaved by specific proteases S1P and S2P in a two-step process to yield the mature SREBP that is translocated into the nucleus, where it activates transcription by binding to specific SREs in the promoter/enhancer regions of multiple target genes. A previous report [104] indicated that simvastatin, in a dose-dependent manner, up regulated the promoter of PON1 gene by increasing SREBP2. But others have reported quite the opposite effect of statins on the PON1 gene regulation [105]. This controversy of PON1 gene regulation has been further complicated by another report showing that dietary polyphenols up regulate PON1 gene expression by aryl hydrocarbon receptor (AhR)-dependent mechanism [106]. Besides PON1 gene regulation via SREBP2 interaction, PON1 gene is also reported to be regulated by Sp1 and protein kinase C (PKC) alpha or zeta, which interacts with the consensus Sp1-binding site in PON1 promoter −269 to −97 bp upstream of transcription initiation site. Over expression of Sp1 dramatically enhances PON1 promoter activity, whereas over expression of PKC significantly reduces PON1 promoter activity [107].

Possible mechanism of action of ethanol

The reduced risk of coronary artery disease associated with moderate alcohol consumption may be explained by its ability to increase plasma HDL [108]. Apart from this, moderate ethanol increases PON1, an HDL-associated antiatherogenic enzyme, that has its cardioprotective action because it (1) hydrolyzes oxidized lipids in OxLDL in serum and macrophages, a prerequisite for the onset of atherosclerosis, (2) inhibits cholesterol uptake by macrophages from OxLDL [24, 108, 109], (3) attenuates macrophage cholesterol biosynthesis and (4) stimulates macrophage cholesterol efflux [20, 108111]. Light ethanol feeding caused a 20–25% increase in PON activity in both serum and liver and a 59% increase in the level of liver PON mRNA compared with pair-fed control rats [24]. Light to moderate alcohol consumption in humans increases the activity of paraoxonase in serum, and the enzymatic activity was strongly correlated with concomitant increases in concentrations of HDL-C and Apo A-I [112]. In humans, light drinking up regulates, whereas heavy drinking down regulates PON activity and its expression, irrespective of its genetic polymorphism [24]. Consequently, PON1 activity is a more reliable predictor of vascular disease status than PON1 genotype. Thus, increased serum paraoxonase may be an important component of the mechanisms underlying the reduction in coronary heart disease following moderate alcohol consumption [113, 114]. However, heavy alcohol consumption (70–90 g/d) resulted in a significant decrease in PON1 and protein thiols, and a significant increase in AST, ALT and GGT levels [115]. It is well known that PON1 loses its activity in the oxidative environment. Therefore, any factors that affect the status of oxidative stress will also affect PON1 activity status. For example, antiphospholipid antibodies increase oxidative stress in experimental mouse model with decreased PON activity [108]. On the other hand, statins commonly used for hypercholesterolemia increase serum PON1 activity by reducing oxidative stress [104].

Possible mechanism of action of polyphenols

We have recently demonstrated [116] that dietary quercetin markedly up regulates hepatic PON1 expression (Fig. 1) accompanied by stimulation of PON1 activity (Table 1) as well as HCTL activity (Table 2) with concomitant increased protection capacity of HDL against LDL oxidation (Table 3). The increase in PON activity may be partially explained by the ability of quercetin to reduce oxidative stress by scavenging oxidative-free radicals. In this regard, our ongoing studies have demonstrated that supplementation of betaine in chronic alcohol-fed rats on high ω3-PUFA diet restored not only serum PON1 activity but also liver GSH, the natural antioxidant [117]. However, our findings clearly indicate that the action of quercetin is not merely because of its antioxidative properties. The fact that hepatic PON1 mRNA level is also increased by 35% (P < 0.01) implies that the action of quercetin must be at the molecular level either at the transcription rate of PON1 gene or at the stabilization of PON1 mRNA. Our ongoing studies (unpublished) in human liver cells seem to indicate that quercetin up regulates PON1 gene via the activation and nuclear translocation of mature SREBP2, which then interacts with SRE elements of PON1 promoter to stimulate its activity. Resveratrol, another polyphenolic compound in red wine, has been reported to have angiogenic and antihypercholesterolemic and antidiabetic effects [118]. The cardioprotective effects of resveratrol was ascribed to increased expression of phospho-Akt, Bcl-2, eNOS, iNOS, COX-1, COX-2, Trx-1 and Trx-2 [119]. In addition, resveratrol inhibits cardiac hypertrophy via AMPK and Akt [119]. Work is currently in progress to elucidate the possible mechanism of actions of ethanol and quercetin in the up-regulation of PON1 at the molecular level.
Fig. 1

Influence of quercetin feeding on the expression of rat PON1 mRNA relative to that of actin mRNA by real-time RT-PCR. A sample of the liver from both control and quercetin-fed groups was analyzed for PON1 mRNA and actin mRNA by real-time RT-PCR, and the relative abundance of PON1 mRNA was determined. Each bar is the mean ± SD of six independent experiments

Table 1

Influence of quercetin feeding on serum and liver PON1 activity

Group

Serum PON1 activity (nmol paraoxon hydrolyzed/ml/min)

P value

Liver PON1 activity (nmol paraoxon hydrolyzed/g/min)

P value

Control

50.13 ± 3.5

 

41.9 ± 13.7

 

Quercetin

64.53 ± 9.1

<0.05

65.69 ± 8.2

<0.01

Serum and liver PON1 enzyme activity was determined with paraoxon (Sigma–Aldrich Inc., St. Louis, MO) as the substrate essentially as described by us previously [23]. Results were expressed as IU. One unit of international enzyme activity was equal to 1 nmol of paraoxon hydrolyzed per minute per ml of serum or per g equivalent of liver microsomes

Table 2

Influence of quercetin feeding on Serum HCTL activity

Group

Serum HCTL activity (nmol HCTL hydrolyzed/ml/min)

P value

Control

6.97 ± 0.52

 

Quercetin

8.57 ± 0.61

<0.05

Serum HCTL activity was determined in an aliquot of the serum of each animal from both control and quercetin-fed groups. Serum HCTL activity was determined essentially as described by us previously [24]. Each value is the mean ± SD of six independent determinations

Table 3

Influence of quercetin feeding on lag time of LDL oxidation by serum HDL

Group

Lag time of LDL oxidation (min)

P Value

Control

67.3 ± 4.2

 

Quercetin

224.1 ± 1.6

<0.001

HDL was isolated from each animal from both control and quercetin-fed groups, and the lag time for its ability to prolong LDL oxidation was determined. Each value is the mean ± SD of six independent determinations

Summary

Based on the comprehensive survey of the current literature and on our own studies, we have summarized the current status of beneficial versus deleterious effects of alcohol/polyphenol with respect to cardioprotection in Fig. 2 below: Accordingly, oxidative stress leads to the oxidation of LDL to form oxidized LDL (OxLDL) that is preferentially taken up by peripheral macrophages via the scavenger receptor pathway forming the foam cells. These cholesterol-laden foam cells accumulate in the intima of the arterial wall leading to occlusion of the artery causing MI. PON1 is an antiatherogenic enzyme that is able to inhibit the oxidation of LDL as well as convert the OxLDL to inactive products. Significantly, when consumed in moderate amounts, ethanol and quercetin, the two major wine components, up regulate PON1 gene and associated increased PON1 activity, and thereby confer cardioprotection. In contrast, heavy ethanol consumption, increased oxidative stress and diabetic conditions have quite the opposite effects on cardioprotection by down regulating PON1 gene.
Fig. 2

Alcohol, polyphenols and PON in CAD protection

Declarations

Acknowledgments

This work was supported by grants from VA Merit Review as well as from NIH (M.R. Lakshman). Authors gratefully acknowledge the Editors of the journal “Biochemical Biophysical Research Communications” for giving permission to reproduce some of the tables and figures reproduced in this review article.

Authors’ Affiliations

(1)
Lipid Research Laboratory, VA Medical Center
(2)
Department of Biochemistry & Molecular Biology, The George Washington University
(3)
Division of Metabolism and Health Effects, National Institute on Alcohol Abuse and Alcoholism National Institutes of Health

References

  1. Gunzerath L, Faden V, Zakhari S, Warren K (2004) National Institutes on alcohol abuse and alcoholism report on moderate drinking. Alcohol Clin Exp Res 28(6):829–847PubMedGoogle Scholar
  2. O’Keefe JH, Bybee KA, Lavie CJ (2007) Alcohol and cardiovascular health. J Am Col Cardiol 50:1009–1014View ArticleGoogle Scholar
  3. Parthasarathy S, Rankin SM (1992) Role of oxidized LDL in atherogenesis. Prog Lipid Res 31:127–143PubMedView ArticleGoogle Scholar
  4. Chisolm GM, Steinberg D (2000) The oxidative modification hypothesis of atherogenesis: an overview. Free Rad Biol Med 28:1815–1826PubMedView ArticleGoogle Scholar
  5. Lakshman MR, Reda D, Materson BJ (1996) Plasma lipid and lipoprotein profiles in hypertensive black vs white men. Am J Cardiol 78:1236–1241PubMedView ArticleGoogle Scholar
  6. Belfrage P, Berg B, Hagerstrand I, Nilsson-Ehle P (1977) Alterations of lipid metabolism in healthy volunteers during long-term ethanol intake. Eur J Clin Invest 7(2):127–131PubMedView ArticleGoogle Scholar
  7. Hulley SB, Cohen R, Widdowson G (1977) Plasma high density lipoprotein cholesterol level- influence of risk factor intervention. J Am Med Assoc 238(21):2269–2271View ArticleGoogle Scholar
  8. Jacqueson A, Richard JL, Ducimetiere P, Warnet JM, Claude JR (1983) HDL cholesterol and alcohol consumption in a French male population. Atherosclerosis 48(2):131–138PubMedView ArticleGoogle Scholar
  9. Klatsky AL, Freidman GD, Siegelaub AB (1974) Alcohol consumption before myocardial infarction. Ann Intern Med 81:294–301PubMedGoogle Scholar
  10. Barboriak JJ, Rimm AA, Anderson AJ, Schmidhoffer M, Tristani FE (1977) Coronary artery occlusion and alcohol intake. Br Heart J 39:289–293PubMedView ArticleGoogle Scholar
  11. Masarei JRL, Puddey IL, Rouse WJ (1986) Effects of alcohol consumption on serum lipoprotein-lipid and apolipoprotein concentrations. Atherosclerosis 60:79–87PubMedView ArticleGoogle Scholar
  12. Haskell WL, Camargo C Jr, Williams PT (1984) Effect of cessation and resumption of moderate alcohol intake on serum HDL subfractions. N Engl J Med 310:805–810PubMedGoogle Scholar
  13. Hartung GH, Foreyt JP, Mitchell RE, Mitchell JG, Reeves RS, Gotto AM (1983) Effect of alcohol intake on HDL cholesterol levels in runners and inactive men. JAMA 249:747–750PubMedView ArticleGoogle Scholar
  14. Cushman P, Barboriak J, Kalbfleisch J (1986) Alcohol: high density lipoproteins, apolipoproteins. Alcohol Clin Exp Res 10(2):154–157PubMedView ArticleGoogle Scholar
  15. Lieber CS (1984) To drink “moderately” or not to drink? N Engl J Med 310:846–848PubMedGoogle Scholar
  16. Kagan A, Yano K, Rhoads GC et al (1981) Alcohol and cardiovascular disease: the Hawaiian experience. Circulation 64(3 Pt 2):III 27–III 31Google Scholar
  17. Lakshman MR, Chirtel SC, Chamber LC (1988) Roles of ω3-fatty acids and ethanol on the regulation of plasma and liver lipids and apo A-I and E in rats. J Nutr 118:1299–1303PubMedGoogle Scholar
  18. Lin RC, Lumeng L, Phelps VL (1989) Serum HDL particles of alcohol fed rats are deficient in apolipoprotein E. Hepatology 9:307–313PubMedView ArticleGoogle Scholar
  19. Marmillot P, Rao MN, Liu Q-H, Chirtel SJ, Lakshman MR (2000) Effect of dietary ω3-fatty acids & ethanol consumption on RCT in rats. Metabolism 49:508–512PubMedView ArticleGoogle Scholar
  20. Rao MN, Marmillot P, Seeff LB, Strader DB, Lakshman MR (2000) HDL from human alcoholics exhibit impaired RCT function. Metabolism 49:1406–1410PubMedView ArticleGoogle Scholar
  21. Croft KD, Puddey IB, Rakic V, Abu-Amsha R et al (1996) Oxidative susceptibility of LDL-influence of regular alcohol use. Alcohol Clin Exp Res 20(6):980–984PubMedView ArticleGoogle Scholar
  22. Kervinen K, Savolainen MJ, Kesaniemi YA (1991) LDL derivatization by acetaldehyde affects lysine residues & B/E receptor binding affinity. Alcohol Clin Exp Res 15(6):1050–1055PubMedView ArticleGoogle Scholar
  23. Kesaniemi YA, Kervinen K, Meittinen TA (1987) Acetaldehyde modification of low density lipoprotein accelerates its catabolism in man. Eur J Clin Invest 17:29–36PubMedView ArticleGoogle Scholar
  24. Rao MN, Marmillot P, Palmer DA, Seeff LJ, Strader DB, Lakshman MR (2003) Light, but not heavy alcohol drinking stimulates paraoxonase by up regulating liver PON mRNA in both rats and humans. Metabolism 52:1287–1294PubMedView ArticleGoogle Scholar
  25. Ohnishi K, Lieber CS (1977) Reconstitution of microsomal ethanol-oxidizing system. J Biol Chem 252:7124–7131PubMedGoogle Scholar
  26. DiLuzio NR (1964) Prevention of the acute ethanol-induced fatty liver by the simultaneous administration of antioxidants. Life Sci 3:113–118PubMedView ArticleGoogle Scholar
  27. DiLuzio NR, Costales F (1965) Inhibition of ethanol and carbon tetrachloride induced fatty liver by antioxidants. Exp Mol Pathol 4:141–154View ArticleGoogle Scholar
  28. DiLuzio NR, Kalish GH (1966) Enhanced peroxidation of lipid in the pathogenesis ethanol induced liver injury. Gastroenterology 50:392–396Google Scholar
  29. Cederbaum AJ (1987) Microsomal generation of hydroxyl radicals: its role in microsomal ethanol oxidizing system (MEOS) activity and requirement for iron. Ann N Y Acad Sci 492:35–49PubMedView ArticleGoogle Scholar
  30. Ahmad FF, Cowan DL, Sun AY (1989) Spin trapping and lipid peroxidation. In: Sun GY, Wood WG, Sun AY (eds) Molecular mechanisms of alcohol. Humana Press, Clifton, pp 257–278Google Scholar
  31. Reinke LA, McCay PB (1991) Alcohol and free radicals. In: Watson RR (ed) Liver pathology and alcohol, vol 99. Humana Press, Clifton, pp 133–168Google Scholar
  32. Esterbauer H, Jurgens G, Quenhenberger O (1987) Autoxidation of human LDL. J Lip Res 28:495–509Google Scholar
  33. Esterbauer H, Striegl G, Puhl H, Rotheneder M (1989) Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6:67–75PubMedView ArticleGoogle Scholar
  34. Klatsky AL (1982) Alcohol and the cardiovascular system. Ann Rev Nutr 2:51–71View ArticleGoogle Scholar
  35. Regan TJ (1984) Alcoholic cardiomyopathy. Prog Cardiovasc Dis 27:141–152PubMedView ArticleGoogle Scholar
  36. Urbano-Marquez A, Estrich R, Navarro-Lopez F (1989) The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 320:409–415PubMedView ArticleGoogle Scholar
  37. Klatsky AL (1990) In hypertension: pathophysiology, diagnosis and management. Raven Press, New York, pp 277–294Google Scholar
  38. Donahue RP, Abbott RD, Reed DW et al (1986) Alcohol and hemorrhagic stroke. The Honolulu heart program. JAMA 255:2311–2314PubMedView ArticleGoogle Scholar
  39. Ettinger PO, Wu CF, De La Cruz C et al (1978) Arrhythmias and the “Holiday Heart”: alcohol-associated cardiac rhythm disorders. Am Heart J 95:555–562PubMedView ArticleGoogle Scholar
  40. Stampfer MJ, Colditz GA, Willet WC (1988) A study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Ed 319:267–273View ArticleGoogle Scholar
  41. Klatsky AL, Armstrong MA, Friedman GD (1986) Relations of alcoholic beverage use to subsequent coronary artery disease hospitalization. Am J Cardiol 58:710–714PubMedView ArticleGoogle Scholar
  42. Yano K, Rhoads GG, Kagan A (1977) Coffee, alcohol and risk of coronary heart disease among Japanese men living in Hawaii. N Engl J Med 297:405–409PubMedView ArticleGoogle Scholar
  43. Scragg R, Stewart A, Jackson R (1987) Alcohol and exercise in myocardial infarction and sudden coronary death in men and women. Am J Epidemiol 126:77–85PubMedGoogle Scholar
  44. Castelli WP, Doyle JT, Gordon T et al (1977) Alcohol and blood lipids. The cooperative lipoprotein phenotyping study. Lancet 2:153–155PubMedView ArticleGoogle Scholar
  45. Cauley JA, Kuller LH, LaPorte RE (1987) Studies on the association between alcohol and HDL cholesterol: possible benefits and risks. Adv Alcohol Subst Abuse 6:53–67PubMedGoogle Scholar
  46. Moore RD, Smith CR, Kwiterovich PO, Pearson TA (1988) Effect of low-dose alcohol use versus abstention on apolipoproteins A-I and B. Am J Med 84:884–896PubMedView ArticleGoogle Scholar
  47. Lucas DL, Brown RA, Wassef M, Giles TD (2005) Alcohol and the cardiovascular system. J Am Coll Cardiol 45:1916–1924PubMedView ArticleGoogle Scholar
  48. Femia R, Natali A, L’Abbate A, Ferrannini E (2006) Coronary atherosclerosis and alcohol consumption: angiographic and mortality data. Arter Thromb Vasc Biol 26:1607–1612View ArticleGoogle Scholar
  49. Vliegenthart R, Oei HHS, van den Elzen APM et al (2004) Alcohol consumption and coronary calcification in a general population. Arch Intern Med 164:2355–2360PubMedView ArticleGoogle Scholar
  50. Schminke U, Luedemann J, Berger K et al (2005) Association between alcohol consumption and subclinical carotid atherosclerosis: the Study of Health in Pomerania. Stroke 36:1746–1752PubMedView ArticleGoogle Scholar
  51. Anonymous (1988) Alcohol and mortality: myth of U-shaped curve. Lancet 2:1292–1293Google Scholar
  52. Kabagambe EK, Baylin A, Ruiz-Narvaez E, Rimm EB, Campos H (2005) Alcohol intake, drinking patterns, and risk of nonfatal acute myocardial infarction in Costa Rica. Am J Clin Nutr 82:1336–1345PubMedGoogle Scholar
  53. Mukamal KJ, Jensen MK, Grønbæk M et al (2005) Drinking frequency, mediating biomarkers, and risk of myocardial infarction in women and men. Circulation 112:1406–1413PubMedView ArticleGoogle Scholar
  54. Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (The INTERHEART study): case-control study. Lancet 364:937–952PubMedView ArticleGoogle Scholar
  55. Mukamal KJ, Chiuve SE, Rimm EB (2006) Alcohol consumption and risk for coronary heart disease in men with healthy lifestyles. Arch Intern Med 166:2145–2150PubMedView ArticleGoogle Scholar
  56. Beulens JW, Rimm EB, Ascherio A, Spiegelman D, Hendriks HF, Mukamal KJ (2007) Alcohol consumption and risk for coronary heart disease among men with hypertension. Ann Intern Med 146:10–19PubMedGoogle Scholar
  57. Djoussé L, Gaziano JM (2007) Alcohol consumption and risk of heart failure in the Physicians’ Health Study I. Circulation 115:34–39PubMedView ArticleGoogle Scholar
  58. Beilin LJ, Puddey IB (2006) Alcohol and hypertension: an update. Hypertension 47:1035–1038PubMedView ArticleGoogle Scholar
  59. Mukamal KJ, Conigrave KM, Mittleman MA et al (2003) Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 348:109–118PubMedView ArticleGoogle Scholar
  60. Veenstra J, Ockhuizen T, van de Pol H, Wedel M, Schaafsma G (1990) Effects of a moderate dose on blood lipids and lipoproteins postprandially and in the fasting state. Alcohol Alcohol 25(4):371–377PubMedGoogle Scholar
  61. Rehm J, Sempos CT, Trevisan M (2003) Alcohol and cardiovascular disease—more than one paradox to consider average volume of alcohol consumption, patterns of drinking and risk of coronary heart disease—a review. J Cardiovasc Risk 10:15–20PubMedView ArticleGoogle Scholar
  62. Mukamal KJ, Maclure M, Muller JE, Mittleman MA (2005) Binge drinking and mortality after acute myocardial infarction. Circulation 112:3839–3845PubMedView ArticleGoogle Scholar
  63. Naimi TS, Brewer RD, Mokdad A, Denny C, Serdula MK, Marks JS (2003) Binge drinking among US adults. JAMA 289:70–75PubMedView ArticleGoogle Scholar
  64. Malyutina S, Bobak M, Kurilovitch S et al (2002) Relation between heavy and binge drinking and all-cause and CV mortality in Novosibirsk, Russia: a prospective cohort study. Lancet 360:1448–1454PubMedView ArticleGoogle Scholar
  65. DiCastelnuovo A, Castanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G (2006) Alcohol dosing and total mortality in men and women. Arch Intern Med 166:2437–2445View ArticleGoogle Scholar
  66. Bantle JP et al (2006) Nutrition recommendations and interventions for diabetes—2006: a position statement of the American Diabetes Association. Diabetes Care 29:2140–2157PubMedView ArticleGoogle Scholar
  67. Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Campbell LV (2003) Moderate alcohol consumption, estrogen replacement therapy, and physical activity are associated with increased insulin sensitivity. Diabetes Care 26:2734–2740PubMedView ArticleGoogle Scholar
  68. Rimm EB, Giovannucci EL, Willett WC et al (1991) Prospective study of alcohol consumption and risk of coronary artery disease in men. Lancet 338(8765):464–468PubMedView ArticleGoogle Scholar
  69. Hein HO, Suadicani P, Gyntelberg F (1996) Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: six year follow up in the Copenhagen male study. BMJ 312(7033):736–741PubMedGoogle Scholar
  70. Lazarus NB, Kaplan GA, Cohen RD, Leu DJ (1991) Change in alcohol consumption and risk of death from all causes & ischaemic heart disease. BMJ 303(6802):553–556PubMedView ArticleGoogle Scholar
  71. Friedman LA, Kimball AW (1986) Coronary heart disease mortality and alcohol consumption in Framingham. Am J Epidemiol 124(3):481–489PubMedGoogle Scholar
  72. Corder R, Mullent W, Khan NQ et al (2006) Red wine procyanidins and vascular health. Nature 444:566PubMedView ArticleGoogle Scholar
  73. Hertog MG, Feskens EJM, Hollman P (1993) Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342(8878):1007–1011PubMedView ArticleGoogle Scholar
  74. Knekt P, Jarvinen R, Reunanen A, Maatela J (1996) Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 312(7029):478–481PubMedGoogle Scholar
  75. Klurfeld DM, Kritchevsky D (1981) Differential effects of alcoholic beverages on experimental atherosclerosis in rabbits. Exp Mol Pathol 34(1):62–71PubMedView ArticleGoogle Scholar
  76. Rimm EB, Yjatsky A, Grobbee D, Stampfer MJ (1996) Review of moderate alcohol consumption and reduced risk of coronary heart disease. BMJ 312(7033):731–736PubMedGoogle Scholar
  77. Renaud S, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary artery disease. Lancet 339(8808):1523–1526PubMedView ArticleGoogle Scholar
  78. St Leger AS, Cochrane AL, Moore F (1979) Factors associated with cardiac mortality in developed countries with reference to the consumption of wine. Lancet 1(8124):1017–1020PubMedView ArticleGoogle Scholar
  79. Aviram M, Rosenblat M, Billeke S, La Du B (1999) Human serum PON is inactivated by oxidized LDL and preserved by antioxidants. Free Rad Biol Med 26:892–904PubMedView ArticleGoogle Scholar
  80. Fuhrman B, Aviram M (2002) Preservation of paraoxonase activity by wine flavonoids. Ann N Y Acad Sci 957:321–324PubMedView ArticleGoogle Scholar
  81. Vigna GB, Costantini F, Aldini G et al (2003) Effect of grape seed extract on low-density lipoprotein susceptibility to oxidation in heavy smokers. Metabolism 52:1250–1257PubMedView ArticleGoogle Scholar
  82. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN (1996) Human serum paraoxonase/arylesterase (PON1) is one member of a multigene family. Genomics 33:498–507PubMedView ArticleGoogle Scholar
  83. La Du BN (1992) Human serum paraoxonase/arylesterase. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon Press, New York, pp 51–91Google Scholar
  84. Chemnitius JM, Losch H, Losch K, Zech R (1983) Organophosphate detoxicating hydrolases in different vertebrate species. Comp Biochem Physiol C 76(1):85–93PubMedView ArticleGoogle Scholar
  85. Saha N, Roy AC, Teo SH, Tay JS, Ratnam SS (1991) Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 40:277–282PubMedView ArticleGoogle Scholar
  86. Mackness MI, Arrol S, Abbott CA, Durrington PN (1993) Is paraoxanase related to atherosclerosis. Chem Biol Interac 87:161–171View ArticleGoogle Scholar
  87. Mackness MI, Walker CH, Carlson LA (1987) Low A-esterase activity in serum of patients with fish-eye disease. Clin Chem 33:587–588PubMedGoogle Scholar
  88. Mackness MI (1989) In: Reiner E, Aldridge WN, Hoskins FCG (eds) Enzymes hydrolysing organophosphorus compounds, pp 202–213Google Scholar
  89. Jaichander P, Selvarajan K, Garelnabi M, Parthasartahy S (2008) Induction of PON1 and apolipoprotein A-1 gene expression by asprin. J Lipid Res 49:2142–2148PubMedView ArticleGoogle Scholar
  90. Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152–154PubMedView ArticleGoogle Scholar
  91. Ng CJ, Wadleigh DJ, Gangopadhyay A (2001) Paraoxonase 2 is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444–44449PubMedView ArticleGoogle Scholar
  92. Draganov DL, Stetson PL, Watson CE, Billecke SS, La Du BN (2000) Rabbit serum PON3 is a HDL associated lactonase and protects LDL against oxidation. J Biol Chem 275:33435–33442PubMedView ArticleGoogle Scholar
  93. Reddy ST, Wadleigh DJ, Grijalva V (2001) Human PON3 is a HDL enzyme with biological activity similar to PON1 but not regulated by oxidized lipids. Arter Throm Vasc Biol 21:542–547Google Scholar
  94. Navab M, Hama-Levy S, Van Lenten BJ et al (1997) Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 99:2005–2019PubMedView ArticleGoogle Scholar
  95. Aviram M, Rosenbalt M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101:1581–1590PubMedView ArticleGoogle Scholar
  96. Shih DM, Gu L, Xia YR et al (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284–287PubMedView ArticleGoogle Scholar
  97. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M (2003) Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107:2775–2779PubMedView ArticleGoogle Scholar
  98. Aviram M, Rosenblat M (2004) Paraoxonase 1, 2, 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 37:1304–1316PubMedView ArticleGoogle Scholar
  99. Jakubowski H (2000) Calcium-dependent human serum homocysteine thiolactone hydrolase. J Biol Chem 275:3957–3962PubMedView ArticleGoogle Scholar
  100. Sierksma A, van der Gaag MS, van Tol A, James RW, Hendriks HF (2002) Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin Exp Res 26(9):1430–1435PubMedGoogle Scholar
  101. Lakshman MR, Gottipati CS, Narasimhan SJ, Munoz J, Marmillot P, Nylon ES (2006) Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism 55:1201–1206PubMedView ArticleGoogle Scholar
  102. Jakubowski H (2007) The molecular basis of homocysteine thiolactone-mediated vascular disease. Clin Chem Lab Med 45:704–1716View ArticleGoogle Scholar
  103. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125–1131PubMedGoogle Scholar
  104. Deakin S, Leviev I, Guernier S, James RW (2003) Simvastatin modulates expression of the PON1 gene: a role for SREBP2. Arter Thromb Biol 23:2083–2089View ArticleGoogle Scholar
  105. Gouedard C, Koum-Besson N, Barouki R, Morel Y (2003) Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofirate and statins. Mol Pharmacol 63(4):945–956PubMedView ArticleGoogle Scholar
  106. Gouedard C, Barouki R, Morel Y (2004) Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol 24(12):5209–5222PubMedView ArticleGoogle Scholar
  107. Osaki F, Ikeda Y, Suehiro T, Ota K, Tsuzura S, Arii K, Kumon Y, Hashimoto K (2004) Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis 176(2):279–287PubMedView ArticleGoogle Scholar
  108. Rozenberg O, Shih DM, Aviram M (2003) Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arter Thromb Vasc Biol 23(3):461–467View ArticleGoogle Scholar
  109. Marmillot P, Rao MN, Liu QH, Chirtel SJ, Lakshman MR (2000) Effect of dietary omega-3 fatty acids and chronic ethanol consumption on reverse cholesterol transport in rats. Metabolism 49(4):508–512PubMedView ArticleGoogle Scholar
  110. Rosenblat M, Vaya J, Shih DM, Aviram M (2005) Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 179(1):69–77PubMedView ArticleGoogle Scholar
  111. Rozenberg O, Shih DM, Aviram M (2005) Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 181(1):9–18PubMedView ArticleGoogle Scholar
  112. van Tol AA, Hendriks HFJB (2001) Moderate alcohol consumption: effects on lipids and cardiovascular disease risk. Curr Opin Lipidol 12:19–23PubMedView ArticleGoogle Scholar
  113. Agarwal DP (2002) Cardioprotective effects of light-moderate consumption of alcohol: a review of putative mechanisms. Alcohol Alcohol 37:409PubMedGoogle Scholar
  114. van der Gaag MS, van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, Hendriks HF (1999) Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomized intervention study in middle-aged men. Atherosclerosis 147:405PubMedView ArticleGoogle Scholar
  115. Prakash M, Shetty JK, Tripathy S, Verma M (2007) Letter to the editor: serum paraoxonase in alcohol abusers associated with alcoholic liver disease. Clin Chim Acta 378:232–234PubMedView ArticleGoogle Scholar
  116. Gong M, Garige M, Varatharajalu R, Marmillot P, Gottipatti C, Leckey LC (2009) Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation. Biochem Biophys Res Commun 379:1001–1004PubMedView ArticleGoogle Scholar
  117. Penumathsa SV, Maulik N (2009) Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can J Physiol Pharmacol 87:275–286PubMedView ArticleGoogle Scholar
  118. Dudley JI, Lekli I, Mukherjee S, Das M, Bertelli AA, Das DK (2008) Does white wine qualify for French paradox? Comparison of the cardioprotective effects of red and white wines and their constituents: resveratrol, tyrosol, and hydroxytyrosol. J Agric Food Chem 56:9362–9373PubMedView ArticleGoogle Scholar
  119. Chan AY, Dolinsky VW, Soltys CM, Viollet B, Baksh S, Light PE, Dyck JRB (2008) Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem 283(35):24194–24201PubMedView ArticleGoogle Scholar

Copyright

© Springer-Verlag 2009